P. Peter Ghoroghchian

Element Science, Inc. operates as a medical device and digital health company. It develops a wearable platform solution with proprietary technology in wearable patches, electrical design, machine learning algorithms and digital solutions. The company was founded by Uday N. Kumar in 2011 and is headquartered in San Francisco, CA.

Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.

HistoWiz, Inc. develops information technology infrastructure to archive and manage multi-terabyte databases for histopathology services. It offers PathologyMap, an online preclinical pathology database allowing online viewing, tagging, collaboration, search, comparison, and analysis of histopathology data across different laboratories and hospitals. The company was founded by Ke Cheng in 2012 and is headquartered in Brooklyn, NY.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Part of Rothschild & Co. The company is based in New York, NY. Continuation Holdings AG, Rothschild, Inc. provides investment banking and advisory services.

Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge.

Red Ventures LLC engages in the development of an online digital consumer platform. It brings consumers and brands together through the use of online marketplaces and strategic partnerships. It serves the healthcare, home services, and financial services industries. The company was founded by Ricardo Luis Elias and Daniel S. Feldstein in 2000 and is headquartered in Fort Mill, SC.

venBio Partners LLC (venBio) is a venture capital subsidiary of Venbio Partners LP founded in 2009 by Adelman robert and Goodman corey. The firm is headquartered in San Francisco, California.

Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA.

Braeburn Pharmaceuticals SPRL develops and commercializes medical products. It’s a pharmaceutical company focused on novel, long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including addiction, pain, and schizophrenia. The firm offers Probuohine, CAM2038q1w, CAM2038q4w and Risperdone implant. The company was founded in 2012 and is headquartered in Road Town, British Virgin Islands.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

Swift Health Systems, Inc. provides healthcare services. It offers dental solutions. The company was founded by John Pham and Hongsheng Tong in 2014 and is headquartered in Irvine, CA.

Marengo Therapeutics, Inc. operates as a biotechnology company that develops immunotherapies. Its product is Universal Targeted Immunotherapy a drug discovery platform that underpins an immunological tumor elimination. The company was founded by Andreas Loew and is headquartered in Cambridge, MA.

Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA.

Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA.

Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA.

Qiming US Ventures Management LLC (Qiming Venture Partners) is a venture capital subsidiary of Qiming Venture Partners Ltd founded in 2017 by Mark D. McDade and Gary Edward Rieschel. The firm is headquartered in Cambridge, Massachusetts.

Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Silagene, Inc. provides health care services. The company is headquartered in Hillsborough, NJ.

Ascidian Therapeutics, Inc. operates as a biotechnology research and development company. The company is headquartered in Brighton, MA.

Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation.

Ablaze Pharmaceuticals is a Chinese clinical-stage pharmaceutical company founded in 2021 with a mission to bring advanced targeted radiopharmaceutical therapies to benefit cancer patients. Ablaze Pharma has secured a partnership with Rayzebio, Inc., an innovative radiopharmaceutical company based in CA, to gain exclusive development and commercial rights to a series of Rayzebio's products in the greater region. The company is based in Jing'an District, China. The company leverages its team's extensive business experience and network in cross-border product development and deal making to become the leader and partner of choice in the emerging TRT market. Alex Qiao has been the CEO of the company since 2021.

35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov.

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.

Attovia Therapeutics manufactures a pipeline for bio therapeutics to immune-mediated diseases including cancer. The company is based in Sacramento, CA. Attovia Therapeutics was founded by Tao Fu and Tao Fu has been the CEO since incorporation.